In silico analyses identify lncRNAs: WDFY3-AS2, BDNF-AS and AFAP1-AS1 as potential prognostic factors for patients with triple-negative breast tumors.

Adaptor Proteins, Signal Transducing / genetics Autophagy-Related Proteins / genetics Brain-Derived Neurotrophic Factor / genetics Computer Simulation Humans Oligonucleotide Array Sequence Analysis Prognosis RNA, Long Noncoding / genetics Triple Negative Breast Neoplasms / diagnosis

Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 05 12 2019
accepted: 10 04 2020
entrez: 14 5 2020
pubmed: 14 5 2020
medline: 30 7 2020
Statut: epublish

Résumé

Long non-coding RNAs (lncRNAs) are characterized as having 200 nucleotides or more and not coding any protein, and several been identified as differentially expressed in several human malignancies, including breast cancer. Here, we evaluated lncRNAs differentially expressed in triple-negative breast cancer (TNBC) from a cDNA microarray data set obtained in a previous study from our group. Using in silico analyses in combination with a review of the current literature, we identify three lncRNAs as potential prognostic factors for TNBC patients. We found that the expression of WDFY3-AS2, BDNF-AS, and AFAP1-AS1 was associated with poor survival in patients with TNBCs. WDFY3-AS2 and BDNF-AS are lncRNAs known to play an important role in tumor suppression of different types of cancer, while AFAP1-AS1 exerts oncogenic activity. Our findings provided evidence that WDFY3-AS2, BDNF-AS, and AFAP1-AS1 may be potential prognostic factors in TNBC development.

Sections du résumé

BACKGROUND
Long non-coding RNAs (lncRNAs) are characterized as having 200 nucleotides or more and not coding any protein, and several been identified as differentially expressed in several human malignancies, including breast cancer.
METHODS
Here, we evaluated lncRNAs differentially expressed in triple-negative breast cancer (TNBC) from a cDNA microarray data set obtained in a previous study from our group. Using in silico analyses in combination with a review of the current literature, we identify three lncRNAs as potential prognostic factors for TNBC patients.
RESULTS
We found that the expression of WDFY3-AS2, BDNF-AS, and AFAP1-AS1 was associated with poor survival in patients with TNBCs. WDFY3-AS2 and BDNF-AS are lncRNAs known to play an important role in tumor suppression of different types of cancer, while AFAP1-AS1 exerts oncogenic activity.
CONCLUSION
Our findings provided evidence that WDFY3-AS2, BDNF-AS, and AFAP1-AS1 may be potential prognostic factors in TNBC development.

Identifiants

DOI: 10.1371/journal.pone.0232284 PMID: 32401758 PMC: PMC7219740
pubmed: 32401758
doi: 10.1371/journal.pone.0232284
pii: PONE-D-19-33735
pmc: PMC7219740
doi:

Substances chimiques

AFAP1-AS1 long noncoding RNA, human 0
Adaptor Proteins, Signal Transducing 0
Autophagy-Related Proteins 0
Brain-Derived Neurotrophic Factor 0
RNA, Long Noncoding 0
WDFY3 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0232284

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Technol Cancer Res Treat. 2019 Jan 1;18:1533033819843889
pubmed: 30983509
J Cancer. 2018 Nov 24;9(24):4627-4634
pubmed: 30588246
Cell Biochem Funct. 2019 Jul;37(5):340-347
pubmed: 31062382
J Cell Physiol. 2020 Feb;235(2):1141-1154
pubmed: 31347170
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1530-1536
pubmed: 30037433
Oncotarget. 2017 Apr 4;8(14):22783-22799
pubmed: 28187000
Mol Oncol. 2019 Jun;13(6):1342-1355
pubmed: 30959550
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Onco Targets Ther. 2018 Nov 09;11:8001-8012
pubmed: 30519041
Breast Cancer (Dove Med Press). 2016 May 20;8:93-107
pubmed: 27284266
Noncoding RNA Res. 2019 Feb 05;4(1):36-44
pubmed: 30891536
Biomed Pharmacother. 2017 Dec;96:14-21
pubmed: 28961506
Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819882949
pubmed: 31672084
Oncol Lett. 2019 Oct;18(4):3817-3822
pubmed: 31516593
J Cell Commun Signal. 2009 Dec;3(3-4):255-73
pubmed: 19809893
Front Oncol. 2018 Feb 22;8:31
pubmed: 29520340
J Cell Biochem. 2019 Dec;120(12):19784-19795
pubmed: 31347720
Cell Physiol Biochem. 2018;50(2):473-488
pubmed: 30308479
Cancer Manag Res. 2018 Dec 10;10:6823-6833
pubmed: 30573992
Curr Oncol. 2018 Jun;25(Suppl 1):S142-S150
pubmed: 29910657
Cancer Biomark. 2018;22(1):49-54
pubmed: 29439313
Cancer Biomark. 2018;22(2):249-256
pubmed: 29630518
Clin J Oncol Nurs. 2010 Dec;14(6):771-83
pubmed: 21112854
Oncotarget. 2018 Feb 28;9(28):20179-20212
pubmed: 29732012
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Nat Biotechnol. 2012 Mar 25;30(5):453-9
pubmed: 22446693
Int J Mol Med. 2009 Jun;23(6):733-43
pubmed: 19424599
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Int J Oncol. 2006 Jun;28(6):1441-61
pubmed: 16685446
Histochem Cell Biol. 2019 Oct;152(4):281-291
pubmed: 31352515
Nature. 2010 Apr 15;464(7291):1071-6
pubmed: 20393566
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Mol Biol Rep. 2018 Dec;45(6):2313-2324
pubmed: 30259245
Cancer Biother Radiopharm. 2018 Aug;33(6):241-251
pubmed: 30048163
Semin Oncol Nurs. 2015 May;31(2):108-21
pubmed: 25951740
Oncologist. 2011;16 Suppl 1:61-70
pubmed: 21278442
Biomed Pharmacother. 2018 Jun;102:1105-1110
pubmed: 29710528
Cancer Cell Int. 2018 Jul 17;18:103
pubmed: 30026672
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Breast Cancer Res Treat. 2011 Feb;126(1):1-14
pubmed: 20369286
Noncoding RNA Res. 2018 Mar 31;3(3):108-117
pubmed: 30175284
Front Pharmacol. 2018 Nov 16;9:1248
pubmed: 30505272
Pathol Oncol Res. 2020 Apr;26(2):1029-1039
pubmed: 30972633
Biochim Biophys Acta Gene Regul Mech. 2020 Apr;1863(4):194378
pubmed: 31048026
Oncotarget. 2018 May 29;9(41):26406-26416
pubmed: 29899867
Biosci Rep. 2018 Nov 15;38(6):
pubmed: 30352834
Cancer Res. 2015 Sep 15;75(18):3728-37
pubmed: 26208906
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cell Cycle. 2019 Aug;18(16):1965-1975
pubmed: 31282278
Oncol Lett. 2017 Nov;14(5):5876-5882
pubmed: 29113221
Cancer Cell Int. 2018 Jul 28;18:107
pubmed: 30069164
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Mol Cell Biol. 2018 Mar;19(3):143-157
pubmed: 29138516
Arch Biochem Biophys. 2018 May 15;646:113-119
pubmed: 29572178
Oncol Rep. 2017 Sep;38(3):1383-1392
pubmed: 28731151
Minerva Med. 2016 Dec;107(6):392-400
pubmed: 27333150

Auteurs

Daniel Rodrigues de Bastos (D)

Discipline of Oncology, Department of Radiology and Oncology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Laboratory of Molecular Genetics, Center for Translational Research in Oncology, Cancer Institute of São Paulo, São Paulo, Brazil.
ORCID: 0000-0001-7091-1959

Maria A Nagai (MA)

Discipline of Oncology, Department of Radiology and Oncology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Laboratory of Molecular Genetics, Center for Translational Research in Oncology, Cancer Institute of São Paulo, São Paulo, Brazil.
ORCID: 0000-0002-0728-4937

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines adaptatrices de la transduction du signal › In silico analyses identify lncRNAs:...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines associées à l'autophagie › In silico analyses identify lncRNAs:...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Facteurs de croissance nerveuse › Facteur neurotrophique dérivé du cerveau › In silico analyses identify lncRNAs:...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Simulation numérique › In silico analyses identify lncRNAs:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › In silico analyses identify lncRNAs:...
questionsmedicales.fr › Techniques d'investigation › Techniques de sonde moléculaire › Séquençage par oligonucléotides en batterie › In silico analyses identify lncRNAs:...
questionsmedicales.fr › Diagnostic › Pronostic › In silico analyses identify lncRNAs:...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › ARN long non codant › In silico analyses identify lncRNAs:...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Tumeurs du sein triple-négatives › In silico analyses identify lncRNAs:...